174 related articles for article (PubMed ID: 26944316)
1. Hexamethylene amiloride engages a novel reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to selectively target breast cancer cells.
Rowson-Hodel AR; Berg AL; Wald JH; Hatakeyama J; VanderVorst K; Curiel DA; Leon LJ; Sweeney C; Carraway KL
Cancer Lett; 2016 May; 375(1):62-72. PubMed ID: 26944316
[TBL] [Abstract][Full Text] [Related]
2. Molecular features of the cytotoxicity of an NHE inhibitor: Evidence of mitochondrial alterations, ROS overproduction and DNA damage.
Aredia F; Czaplinski S; Fulda S; Scovassi AI
BMC Cancer; 2016 Nov; 16(1):851. PubMed ID: 27816051
[TBL] [Abstract][Full Text] [Related]
3. Methylglyoxal at metronomic doses sensitizes breast cancer cells to doxorubicin and cisplatin causing synergistic induction of programmed cell death and inhibition of stemness.
Roy A; Sarker S; Upadhyay P; Pal A; Adhikary A; Jana K; Ray M
Biochem Pharmacol; 2018 Oct; 156():322-339. PubMed ID: 30170097
[TBL] [Abstract][Full Text] [Related]
4. A cell-permeant amiloride derivative induces caspase-independent, AIF-mediated programmed necrotic death of breast cancer cells.
Leon LJ; Pasupuleti N; Gorin F; Carraway KL
PLoS One; 2013; 8(4):e63038. PubMed ID: 23646172
[TBL] [Abstract][Full Text] [Related]
5. Multiple effects of the Na(+)/H (+) antiporter inhibitor HMA on cancer cells.
Aredia F; Giansanti V; Mazzini G; Savio M; Ortiz LM; Jaadane I; Zaffaroni N; Forlino A; Torriglia A; Scovassi AI
Apoptosis; 2013 Dec; 18(12):1586-98. PubMed ID: 23996609
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy.
Luo J; Tannock IF
Br J Cancer; 1994 Oct; 70(4):617-24. PubMed ID: 7917906
[TBL] [Abstract][Full Text] [Related]
7. C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: a mechanism study.
Yang L; Zheng LY; Tian Y; Zhang ZQ; Dong WL; Wang XF; Zhang XY; Cao C
Exp Cell Res; 2015 Mar; 332(1):47-59. PubMed ID: 25576381
[TBL] [Abstract][Full Text] [Related]
8. Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
Buckley BJ; Aboelela A; Majed H; Bujaroski RS; White KL; Powell AK; Wang W; Katneni K; Saunders J; Shackleford DM; Charman SA; Cook GM; Kelso MJ; Ranson M
Bioorg Med Chem; 2021 May; 37():116116. PubMed ID: 33799173
[TBL] [Abstract][Full Text] [Related]
9. A Novel Naphthotriazolyl-4-oxoquinoline Derivative that Selectively Controls Breast Cancer Cells Survival Through the Induction of Apoptosis.
Branco JR; Oliveira VG; Esteves AM; Chipoline IC; Lima MFO; Boechat FCS; da Silva FC; Ferreira VF; Sola-Penna M; de Souza MCBV; Zancan P
Curr Top Med Chem; 2018; 18(17):1465-1474. PubMed ID: 30129412
[TBL] [Abstract][Full Text] [Related]
10. Participation of autophagy in the cytotoxicity against breast cancer cells by cisplatin.
Shen M; Duan WM; Wu MY; Wang WJ; Liu L; Xu MD; Zhu J; Li DM; Gui Q; Lian L; Gong FR; Chen K; Li W; Tao M
Oncol Rep; 2015 Jul; 34(1):359-67. PubMed ID: 26005215
[TBL] [Abstract][Full Text] [Related]
11. Triggering autophagic cell death with a di-manganese(II) developmental therapeutic.
Slator C; Molphy Z; McKee V; Kellett A
Redox Biol; 2017 Aug; 12():150-161. PubMed ID: 28236767
[TBL] [Abstract][Full Text] [Related]
12. The Cationic Amphiphilic Drug Hexamethylene Amiloride Eradicates Bulk Breast Cancer Cells and Therapy-Resistant Subpopulations with Similar Efficiencies.
Berg AL; Rowson-Hodel A; Hu M; Keeling M; Wu H; VanderVorst K; Chen JJ; Hatakeyama J; Jilek J; Dreyer CA; Wheeler MR; Yu AM; Li Y; Carraway KL
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205696
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA).
Matthews H; Ranson M; Tyndall JD; Kelso MJ
Bioorg Med Chem Lett; 2011 Nov; 21(22):6760-6. PubMed ID: 21978672
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance.
Skildum A; Dornfeld K; Wallace K
Breast Cancer Res Treat; 2011 Oct; 129(3):785-97. PubMed ID: 21128112
[TBL] [Abstract][Full Text] [Related]
15. SZC017, a novel oleanolic acid derivative, induces apoptosis and autophagy in human breast cancer cells.
Gao L; Wang Y; Xu Z; Li X; Wu J; Liu S; Chu P; Sun Z; Sun B; Lin Y; Peng J; Han G; Wang S; Tang Z
Apoptosis; 2015 Dec; 20(12):1636-50. PubMed ID: 26407982
[TBL] [Abstract][Full Text] [Related]
16. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
17. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Buckley BJ; Aboelela A; Minaei E; Jiang LX; Xu Z; Ali U; Fildes K; Cheung CY; Cook SM; Johnson DC; Bachovchin DA; Cook GM; Apte M; Huang M; Ranson M; Kelso MJ
J Med Chem; 2018 Sep; 61(18):8299-8320. PubMed ID: 30130401
[TBL] [Abstract][Full Text] [Related]
18. Fluorescence properties of the Na⁺/H⁺exchanger inhibitor HMA (5-(N,N-hexamethylene)amiloride) are modulated by intracellular pH.
Giansanti V; Santamaria G; Torriglia A; Aredia F; Scovassi AI; Bottiroli G; Croce AC
Eur J Histochem; 2012 Jan; 56(1):e3. PubMed ID: 22472891
[TBL] [Abstract][Full Text] [Related]
19. Carotenoid Lutein Selectively Inhibits Breast Cancer Cell Growth and Potentiates the Effect of Chemotherapeutic Agents through ROS-Mediated Mechanisms.
Gong X; Smith JR; Swanson HM; Rubin LP
Molecules; 2018 Apr; 23(4):. PubMed ID: 29662002
[TBL] [Abstract][Full Text] [Related]
20. Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
Black M; Barsoum IB; Truesdell P; Cotechini T; Macdonald-Goodfellow SK; Petroff M; Siemens DR; Koti M; Craig AW; Graham CH
Oncotarget; 2016 Mar; 7(9):10557-67. PubMed ID: 26859684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
